NCT06749054 - Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 26, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions

HIV-1-infection

Interventions

DRUG

Oral Lenacapavir

Tablets administered without regard to food

DRUG

Subcutaneous Lenacapavir

Administered via subcutaneous injections

DRUG

Optimized Background Regimen (OBR)

Optimized background regimen as prescribed by the Investigator

Trial Locations (7)

RECRUITING

Perinatal HIV Research Unit (PHRU), Soweto

RECRUITING

Wits RHI Shandukani Research Centre CRS, Johannesburg

RECRUITING

Rahima Moosa Mother and Child Hospital, Johannesburg

RECRUITING

Durban International Clinical Research Site, Enhancing Care Foundation, KwaZulu - Natal

RECRUITING

FAMCRU, Cape Town

RECRUITING

Be Part Research Pty (Ltd), Paarl

RECRUITING

Grady Health System, Ponce De Leon Center, Atlanta